by Colleen Fleiss on  May 12, 2018 at 11:18 PM Drug News
New Insights into Anti-rheumatic Drugs
Stopping tumor necrosis factor inhibitors in patients with stable low disease activity, on average, was associated with a cost saving of 7,133, a loss of 0.022 quality-adjusted life years, and an increase of 0.41 arthritis flares per patient per year, reveals study published in Arthritis & Rheumatology.

In the study, "The subpopulation of patients receiving biological disease modifying anti-rheumatic drugs including tumor necrosis factor inhibitors... has increased over time and accounted for up to 20% of the population of rheumatoid arthritis patients in various Western healthcare systems," the authors wrote.

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints and the surrounding tissues. It is an autoimmune disease.


Source: Eurekalert

Most Popular on Medindia